Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SPRINTEC vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrium to prevent pregnancy.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women at least 15 years of age who have achieved menarche and are seeking an oral contraceptive
Prevention of pregnancy (FDA-approved)
One tablet (0.25 mg norgestimate, 0.035 mg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo tablets.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Ethinyl estradiol: 13 ± 3 hours (variable, influenced by CYP3A4 activity); Norgestimate: 1.5-2 hours (rapidly converted to norelgestromin); Norelgestromin: 12-20 hours (active metabolite); clinical context: dosing interval of 24 hours supports once-daily administration.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol is metabolized primarily by CYP3A4; norgestimate is rapidly metabolized to norelgestromin and norgestrel via first-pass metabolism.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: approximately 50-60% (metabolites, primarily glucuronide conjugates), Fecal: approximately 30-40% (biliary excretion of metabolites), with minimal unchanged drug in urine (<5%).
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Ethinyl estradiol: >97% bound to albumin; Norgestimate/norelgestromin: 99% bound to albumin and sex hormone-binding globulin (SHBG).
~99% bound to serum albumin and sex hormone-binding globulin.
Ethinyl estradiol: 2.5-4.0 L/kg; Norgestimate: not determined (extensive tissue distribution); clinical meaning: reflects distribution into total body water and tissues.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Ethinyl estradiol: 38-48% due to first-pass metabolism; Norgestimate: 100% (prodrug, rapidly hydrolyzed in gut wall and liver).
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment; use caution.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in patients with acute or chronic hepatic dysfunction (Child-Pugh class B or C). No data for mild impairment; use with caution.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Safety and efficacy have not been established in postmenarchal pediatric patients. Use after first menses; dosing same as adults.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women. No specific dose adjustment needed for elderly patients beyond contraindications.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptive use. Risk increases with age (>35 years) and number of cigarettes smoked. Women over 35 who smoke should not use combined oral contraceptives.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders,Increased risk of myocardial infarction and stroke, especially in smokers,Increased risk of hepatic neoplasia,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Avoid grapefruit juice as it may increase estrogen levels and risk of adverse effects. No other significant food interactions are known; maintain consistent dietary habits to minimize gastrointestinal side effects.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
FDA Pregnancy Category X. Use contraindicated in pregnancy. First trimester: Major congenital anomalies including cardiovascular and limb defects; increased risk of neural tube defects. Second and third trimesters: Fetal genital abnormalities in females (diethylstilbestrol-like effect); potential for long-term reproductive tract changes. Postnatal: Possible increased risk of neurodevelopmental issues.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Excreted in human breast milk with milk-to-plasma ratio approximately 0.5. Potential adverse effects in nursing infant including jaundice and breast enlargement. Use during lactation not recommended unless clearly necessary. May reduce milk production and quality.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No dose adjustments approved; contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) could reduce efficacy if used, but use is contraindicated.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
SPRINTEC (ethinyl estradiol/norgestimate) is a combined oral contraceptive. Prescribe with caution in women with migraine with aura due to increased stroke risk. If a dose is missed, take as soon as remembered; if >24 hours late, use backup contraception for 7 days. Monitor blood pressure at initiation and annually. Discontinue if pregnancy is suspected or confirmed. Advise that antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at the same time each day, in the order directed on the pill pack.,If you miss a pill, refer to the package insert or consult your healthcare provider; use backup contraception as directed.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding; these often improve within a few cycles.,Seek immediate medical attention for symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or sudden severe headache.,Inform your provider about all medications, including over-the-counter drugs and herbal supplements, especially St. John's Wort.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SPRINTEC vs AFIRMELLE, answered by our medical review team.
SPRINTEC is a Oral Contraceptive that works by Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrium to prevent pregnancy.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SPRINTEC and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SPRINTEC is: One tablet (0.25 mg norgestimate, 0.035 mg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo tablets.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SPRINTEC and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SPRINTEC is classified as Category C. FDA Pregnancy Category X. Use contraindicated in pregnancy. First trimester: Major congenital anomalies including cardiovascular and limb defects; increased risk of neural tube def. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.